Prevention of a first episode of variceal bleeding: role of duplex Doppler sonographic measurement of the acute response to beta-blockers.
The aim of our study was to assess whether acute variations in portal vein Doppler sonographic parameters induced by administration of a single beta-blocker agent are predictive of the long-term effects of these drugs in the prevention of a first episode of variceal bleeding. In 30 patients with liver cirrhosis at high risk for variceal bleeding, duplex Doppler sonographic parameters (maximal portal flow velocity, portal blood flow, and congestion index) were measured before and 4 h after the administration of 40 mg of propranolol. Twenty-three of these patients started chronic therapy with propanolol and were evaluated periodically (seven patients were excluded because they did not continue the therapy). The percentage of patients free from bleeding was 86.9% at the first year and 77.8% at the second year. Among a series of clinical, laboratory, and instrument-based parameters, the only one related to first bleeding, selected by the Cox regression model, was the percentage decrease in maximal portal flow velocity observed after initial administration of propranolol (P < 0.01). The best cutoff value for the percentage decrease in portal flow velocity (portal flow velocity test) was 12%. The prevalence of bleeding had been 25% (3 of 12) in patients with positive portal flow velocity test results (12% decrease or more), versus 64% (7 of 11) in patients with negative portal flow velocity test results. The actuarial probability of remaining free from bleeding (Kaplan-Meier analysis) was different in these two groups (log rank P < 0.01). The portal flow velocity test represents a safe and feasible method to predict the efficacy of beta-blockers in the prevention of a first bleeding episode in patients with cirrhosis. In patients with negative results on the portal flow velocity test, an alternative therapeutic approach should be considered.
Cioni
G
G
Department of Internal Medicine, Azienda Ospedaliera Policlinico, Modena, Italy.
Turrini
F
F
Tincani
E
E
D'Alimonte
P
P
Cristani
A
A
Boldrini
E
E
Baraldi
E
E
Pedrazzini
P G
PG
Ventura
P
P
Ventura
E
E
D000206:Actuarial Analysis; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D001783:Blood Flow Velocity / Q000187:drug effects; D004932:Esophageal and Gastric Varices / Q000000981:diagnostic imaging / Q000517:prevention & control*; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D006471:Gastrointestinal Hemorrhage / Q000000981:diagnostic imaging / Q000517:prevention & control*; D006801:Humans; D008103:Liver Cirrhosis / Q000000981:diagnostic imaging / Q000188:drug therapy; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011169:Portal Vein / Q000000981:diagnostic imaging / Q000187:drug effects; D015995:Prevalence; D011379:Prognosis; D016016:Proportional Hazards Models; D011433:Propranolol / Q000627:therapeutic use*; D012372:ROC Curve; D012039:Regional Blood Flow / Q000187:drug effects; D012449:Safety; D018616:Ultrasonography, Doppler, Duplex
D000319:Adrenergic beta-Antagonists; D011433:Propranolol